Inclusion Criteria:

- Histologically diagnosed HCC, OR clinically diagnosed HCC

- Inoperable tumor(s) and no applicable curative therapy. Not amenable to loco-regional
therapy

- Documented progression with or intolerance to sorafenib treatment as first- line
therapy for advanced HCC

- At least one measurable tumor, according to RECIST version 1.1, that has not been
treated with any local procedure

- ECOG performance status 0 or 1

- Life expectancy is at least 2 months

- Child-Pugh class A liver function.

Exclusion Criteria:

- Systemic therapy other than sorafenib as first-line therapy for advanced HCC

- History of HCC tumor rupture

- Presence of brain or leptomeningeal metastases

- Esophageal/gastric varices or active peptic ulcers that are considered to have high
risk of bleeding

- History of upper gastrointestinal bleeding within 1 year

- Major systemic diseases that the investigator considers inappropriate for
participation

- Uncontrollable hypertension

- Proteinuria

- Current use or anticipated need for treatment with potent CYP3A4 inhibitor, CYP3A4 or
CYP1A2 inducers

- Requirement of anticoagulant therapy with oral vitamin K antagonists

- Dementia or significantly altered mental status that would prohibit the understanding
or rendering of informed consent and compliance with the requirements of this
protocol

- Other severe acute or chronic medical or psychiatric condition, or laboratory
abnormality that may increase the risk associated with study participation and in the
judgment of the investigator would make the patient inappropriate for entry into this
study